Rheumatoid Arthritis Diagnostic Tests Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Rheumatoid Arthritis Diagnostic Tests Market is segmented by Test Type (Serology Test (Erythrocyte Sedimentation Rate (ESR), Anti-cyclic Citrullinated Peptide (anti-CCP), Rheumatoid Factor (RF), Others)) Monitoring Rheumatoid Arthritis Treatment Efficiency Tests (Salicylate Level Count, Muscle Enzyme Tests, Creatinine Test)), End Users (Hospitals, Clinics & Other End Users (Research Institutes, Laboratories), Geography (North America, Europe, Asia-Pacific, South America, Middle East, and Africa). The report offers the value (in USD million) for the above segments.

Market Snapshot

Rheumatoid Arthritis Diagnostic Tests Market Size
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 5.1 %
Rheumatoid Arthritis Diagnostic Tests Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The rheumatoid arthritis diagnostic tests market is expected to register a CAGR of 5.1% over the forecast period 2022-2027.

The COVID-19 pandemic had a significant impact on the market for the rheumatoid arthritis diagnostic test market at the beginning. The COVID-19 outbreak affected the market's growth adversely in its preliminary phase; however, the number of rheumatoid arthritis patients increased, and so has the demand for the rheumatoid arthritis diagnostic test market. According to the article published in 2021 on PubMed Central, “COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges” explains that the management of rheumatoid arthritis patients in the COVID-19 context is a difficult task in and of itself. Even though online consultations are advisable with patients who are having stable rheumatoid arthritis.

Further, the high prevalence of rheumatoid arthritis, favorable health reimbursement, and increased awareness regarding Rheumatoid arthritis among people and clinicians is a major factor in the rheumatoid arthritis diagnostic tests market, thereby contributing to market growth. The 2022 article published in the National Library of Medicine, explains about the awareness of rheumatoid arthritis has a high genetic component and cannot be completely avoided; however, modifiable risk factors including smoking and eating a well-balanced diet should be addressed. Patients at risk for rheumatoid arthritis should be advised to eat a well-balanced diet, exercise on a regular basis, and keep a healthy weight.

Moreover, market players are involved in marketing strategies like mergers, acquisitions product launches for instance in 2022, specialty Network LLC acquired United Rheumatology LLC. By collaborating with Specialty Networks, community Rheumatology clinics will be able to maintain their independence while also improving the standard of treatment for their patients.

Furthermore, new product releases and strategic efforts by prominent market competitors are favorably impacting the industry's growth. For example, there is an ongoing trial (last updated January 2020) under the title “Prediction Medical Device for Rheumatoid Arthritis (PREDIRA) (PREDIRA)” sponsored by Hospital San Carlos, Madrid, on clinicaltrial.gov, which explains a new device for individuals with rheumatoid arthritis, SinnoTest. Through the examination of the patient's particular protein biomarkers, SinnoTest can identify the likelihood of biotherapy treatment response. As a result, the SinnoTest allows for the best biotherapy selection.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, the non-reliance on rheumatoid arthritis testing measures restrains the market growth.

Scope of the Report

As per the scope of the report, rheumatoid arthritis diagnostic tests are tests used to detect rheumatoid arthritis that is characterized by inflammation of the joints and the subsequent destruction of cartilage and erosion of the bone. Early diagnostic tests and prompt treatment can lead to proper recovery. The rheumatoid arthritis diagnostic tests market is segmented by Test Type (Serology Test (Erythrocyte Sedimentation Rate (ESR), Anti-cyclic Citrullinated Peptide (anti-CCP), Rheumatoid Factor (RF), Others)) Monitoring Rheumatoid Arthritis Treatment Efficiency Tests (Salicylate Level Count, Muscle Enzyme Tests, Creatinine Test)), End Users (Hospitals, Clinics & Other End Users (Research Institutes, Laboratories), Geography (North America, Europe, Asia-Pacific, South America, Middle East, and Africa). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Test Type
Serology Test
Erythrocyte Sedimentation Rate (ESR)
Anti-cyclic Citrullinated Peptide (anti-CCP)
Rheumatoid Factor (RF)
Others
Monitoring Rheumatoid Arthritis Treatment Efficiency Tests
Salicylate Level Count
Muscle Enzyme Tests
Creatinine Test
By End-User
Hospitals
Clinics
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Anti-cyclic Citrullinated Peptide (anti-CCP) tests are Expected to Witness a Healthy Growth Over the Forecast Period

Anti-cyclic Citrullinated Peptide (anti-CCP) tests are used to detect and diagnose Rheumatoid arthritis. Antibodies called anti- Citrullinated Peptides are created by the human immune system. People who test positive for anti-Citrullinated Peptides are more prone to develop rheumatoid arthritis. As per the article “Meta-analysis: compared with anti-CCP and rheumatoid factor, could anti-MCV be the next biomarker in the rheumatoid arthritis classification criteria?” published in 2019, says that the specificity and sensitivity of detecting rheumatoid arthritis by Anti-cyclic Citrullinated Peptide test are high compared to other diagnostic tests.

The article “Diagnostic value of anti-cyclic citrullinated peptide antibody combined with rheumatoid factor in rheumatoid arthritis in Asia: a meta-analysis” was published in the Journal of International Medical Research Central in 2021, explains that Anti-cyclic Citrullinated Peptide and rheumatoid factor combined detection improves the diagnostic efficiency of rheumatoid arthritis. The study gave more scope to the diagnosis of rheumatoid arthritis by Anti-cyclic Citrullinated Peptide (anti-CCP) test thereby increasing the market for the same.

As a result of the aforementioned factors, the Anti-cyclic Citrullinated Peptide (anti-CCP) test segment is predicted to increase significantly over the forecast period.

Rheumatoid Arthritis Diagnostic Tests Market Share

North America is Expected to Grow the Rheumatoid Arthritis Diagnostic Test Market

Driven by the high prevalence of rheumatoid arthritis, favorable health reimbursement, and increased awareness, North America to emerge as the leading region for the rheumatoid arthritis diagnostic test market. According to the Centers for Disease Control and Prevention, the projected prevalence of US adults who will report doctor-diagnosed arthritis report in 2020 seems to be 63 million. This region's rise can be related to a spike in arthritis in the United States and the rest of North America. According to the press release in February 2020 by imaware, announcing the launch of the At-Home Rheumatoid Arthritis Screening Test, designed by healthcare company Micro drop. The imaware test for Rheumatoid Arthritis uses just a few drops of blood to detect unique biomarkers as well as two additional biomarkers to provide more comprehensive results. Thus, properly detecting rheumatoid arthritis will lead to fewer complications in the future. These kinds of developments in the healthcare system and rising health expenditures, as well as increased knowledge of advanced rheumatoid arthritis treatments, are fueling the rheumatoid arthritis market in North America.

Moreover, the factors involved in the growth of the rheumatoid arthritis diagnostic tests market include key product launches increased awareness and manufacturers’ presence in the country. In 2021 May, the Georgia-based Arthritis Foundation announces the launch of a new app (Vim, the Arthritis Foundation's mobile app) and kicks off Arthritis Awareness Month with the release of key findings from a patient study.

The studied market is predicted to grow in the North American region as a result of the above-mentioned reasons.

Rheumatoid Arthritis Diagnostic Tests Market Growth

Competitive Landscape

The rheumatoid arthritis diagnostic tests market is moderately fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known. Include Abbott Laboratories, Augurex Life Sciences Corp., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Beckman Coulter, Inc. among others.

Recent Development

In May 2022, During Arthritis Awareness Month, United Rheumatology and CreakyJoints launch a rheumatoid arthritis resource. According to a news release, United Rheumatology and CreakyJoints have announced a partnership to develop the Rheumatoid Arthritis Wellness Center, a digital resource aimed at aiding those living with rheumatoid arthritis.

In September 2021, Myriad Genetics' Vectra Testing Business was acquired by Labcorp from Myriad Autoimmune. Vectra is a blood-based, non-invasive test to assess the severity of rheumatoid arthritis disease and the effectiveness of existing treatments. It can also predict the chance of joint deterioration in the future. 

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Rheumatoid Arthritis

      2. 4.2.2 Favorable health reimbursement and increased awareness

    3. 4.3 Market Restraints

      1. 4.3.1 Non-reliance of rheumatoid arthritis testing measures

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Test Type

      1. 5.1.1 Serology Test

        1. 5.1.1.1 Erythrocyte Sedimentation Rate (ESR)

        2. 5.1.1.2 Anti-cyclic Citrullinated Peptide (anti-CCP)

        3. 5.1.1.3 Rheumatoid Factor (RF)

        4. 5.1.1.4 Others

      2. 5.1.2 Monitoring Rheumatoid Arthritis Treatment Efficiency Tests

        1. 5.1.2.1 Salicylate Level Count

        2. 5.1.2.2 Muscle Enzyme Tests

        3. 5.1.2.3 Creatinine Test

    2. 5.2 By End-User

      1. 5.2.1 Hospitals

      2. 5.2.2 Clinics

      3. 5.2.3 Other End Users

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Siemens Healthineers AG

      3. 6.1.3 Thermo Fisher Scientific Inc.

      4. 6.1.4 Exagen Inc.

      5. 6.1.5 Svar Life Science

      6. 6.1.6 Augurex Life Sciences Corp.

      7. 6.1.7 Danaher Corporation (Beckman Coulter, Inc.)

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Rheumatoid Arthritis Diagnostic Tests Market market is studied from 2019 - 2027.

The Global Rheumatoid Arthritis Diagnostic Tests Market is growing at a CAGR of 5.1% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Abbott Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Beckman Coulter, Inc. , Augurex Life Sciences Corp. are the major companies operating in Global Rheumatoid Arthritis Diagnostic Tests Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!